Chinese cancer biotech Gracell Biotechnologies files for a $100 million US IPO
[unable to retrieve full-text content]
… negative stringent complete responses in relapsed or refractory multiple myeloma patients in an ongoing investigator-initiated Phase 1 trial in China.
Published at Sat, 19 Dec 2020 00:33:45 +0000